ArticleAnnals of surgical oncology2025
The Association of Clinical Stage at Presentation with Overall Survival of Patients who have HER2-Positive Breast Cancer Treated with Neoadjuvant Chemotherapy.
Article in Annals of surgical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPathologic complete response (pCR) to neoadjuvant chemotherapy (NAC) in human epidermal growth factor receptor 2-positive (HER2+) breast cancer is associated with improved survival. This study evaluated the association of disease extent at presentation and response to NAC with overall survival (OS) in HER2+ breast cancer.
methodsPatients with clinical stage I to III HER2+ breast cancer (2013-2020) who underwent NAC and received HER2-targeted therapy were identified from the National Cancer Database. Overall survival was assessed by clinical stage at presentation and chemotherapy response, stratified by hormone receptor (HR) status using multivariable Cox proportional hazards regression.
resultsThe study included 57,671 patients. Among the patients with pCR, OS at 5 years was 98% for stage I, 97% for stage II, and 91% for stage III disease (p < 0.001). Among patients with residual disease, OS at 5 years was 95% for stage I, 91% for stage II, and 80% for stage III disease (p < 0.001). Multivariable analysis showed that stage III HR-/HER2+ disease with pCR did not have OS different from stage I breast cancer with residual disease (hazard ratio, 1.17; p = 0.34). Stage II HR+/HER2+ disease with pCR did not have OS different from stage I breast cancer with residual disease (hazard ratio, 0.94; p = 0.61), and stage III disease with pCR had worse OS (hazard ratio, 1.90; p < 0.001).
conclusionsAmong the patients who had HER2+ breast cancer treated with NAC, the clinical stage at presentation was associated with OS for those with pCR and residual disease. Patients with stage III HER2+ breast cancer and those with stage II HR+/HER2+ breast cancer who achieve pCR could benefit from further studies that evaluate potential escalation of adjuvant therapies.
Indexed as
Identifiers
40810832What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.